MarketInOut Stock Screener Log In | Sign Up
 

Trevi Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/11/2026
Trevi Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,265.37 mln
Float128 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

28.18
Transformational upside

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

0.00
Debt-free

ROE

-23.99
Deeply negative

ROA

-23.00
Deeply negative

Business Description

Trevi Therapeutics is a clinical-stage drug development company focused on treating persistent coughing in patients with serious lung conditions, including idiopathic pulmonary fibrosis and other related diseases. Its lead drug candidate, Haduvio, is a slow-release oral pill currently being tested in multiple clinical trials. The company holds a licensing agreement with Keenova Therapeutics to develop and sell medicines based on the active ingredient nalbuphine hydrochloride. Founded in 2011, Trevi Therapeutics operates out of New Haven, Connecticut.

Key Fundamentals

EPS-0.35
ROE-23.99
ROIC-1,231
ROA-23.00
EBITDA, mln-55.43
EV / EBITDA-37.41
EV / EBIT-37.32

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price28.18
Short Ratio7.68
Short % of Float9.36

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -6.8% 15 / 100   
1 Month -10.32% 19 / 100   
2 Months 14.14% 86 / 100   
6 Months 41.96% 91 / 100   
1 Year 65.28% 91 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us